Mimori K, Mori M, Baba H, Maehara Y, Sugimachi K
Department of Surgery, Kyushu University, Beppu, Japan.
Surg Today. 1995;25(8):741-4. doi: 10.1007/BF00311492.
A complete response to a new chemotherapeutic agent, S1, was achieved in a 64-year-old Japanese man with advanced transverse colon cancer. S1 is a combination of the agents tegafur, 5-chloro-2,4-dihydroxypyridine, and oxonic acid. Because the patient was considered to be a high operative risk due to his poor general condition, S1 was administered at 100 mg/day for 5 days/week over 12 weeks. However, as the serum carcinoembryonic antigen level continued to gradually increase, partial resection of the transverse colon was finally performed. Histopathological study of the resected specimen showed mucin pools in the colon wall with no residual viable cancer cells. No perioperative complications were recognized and the patient is now leading a normal life 6 months after his operation without any signs of recurrence.
一名64岁患有晚期横结肠癌的日本男性患者对新型化疗药物S1产生了完全缓解。S1是替加氟、5-氯-2,4-二羟基吡啶和奥索酸的组合制剂。由于该患者全身状况较差，被认为手术风险较高，因此给予S1，剂量为100毫克/天，每周给药5天，持续12周。然而，由于血清癌胚抗原水平持续逐渐升高，最终对横结肠进行了部分切除。切除标本的组织病理学研究显示结肠壁有黏液池，无残留存活癌细胞。未发现围手术期并发症，患者术后6个月现正过着正常生活，无任何复发迹象。
